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A striking immunologic abnormality of normal and
SCID Tgfb1±/± mice is the total absence of
Langerhans cells in their epidermis. Here we show
that transfer of Tgfb1+/± SCID bone marrow causes,
within a few weeks, the appearance of Langerhans
cells in the epidermis of g-irradiated and unirradiated
Tgfb1±/± SCID recipients. In addition, local injection
of 2 3 105 latent transforming growth factor-b1
cDNA-transduced cloned CD4+ T lymphocytes
causes the appearance of Langerhans cells in the ear
epidermis of Tgfb1±/± SCID mice. This effect is
enhanced by antigen-speci®c activation of these T
cells. Injection of recombinant active transforming
growth factor-b2 into the ear of Tgfb1±/± SCID mice
also results in the migration of Langerhans cells into
the epidermis locally, but no epidermal Langerhans
cells are seen after systemic injections of transform-
ing growth factor-b2. Our results suggest that trans-
forming growth factor-b can act in paracrine as well
as autocrine fashion to induce the differentiation of
precursors into Langerhans cells. Furthermore, these
results indicate that the relative roles of different
transforming growth factor-b isoforms in vivo may
be in¯uenced by their local availability and/or the
regulation of their conversion from latent into active
form. Key words: antigen presentation/cytokines/trans-
genic/knockout. J Invest Dermatol 117:1574±1580, 2001
W
hen carried to term, Tgfb1±/± mice develop
lymphocytic in®ltrations in multiple organs,
including the heart, which are independent
from the presence of infectious agents (Boivin et
al, 1995, 1997). That these in®ltrates contribute
to the early demise of Tgfb1±/± mice at < 1 mo of age is supported
by the observation that lack of transforming growth factor (TGF)-
b1 on an outbred SCID background allows the mice to live for
several months, although they still exhibit an enhanced death rate
during fetal life and have somewhat lower body weights than their
Tgfb1+/± littermates (Diebold et al, 1995). Langerhans cells are the
outposts of the antigen-presenting cell system in the epidermis
(Thorbecke et al, 1984). Another immunologic abnormality of
Tgfb1±/± mice is the total absence of these cells in their epidermis
(Borkowski et al, 1997a,b). This is not the result of a destruction of
Langerhans cells by in®ltrating lymphocytes, because this defect is
seen whether Tgfb1±/± mice are bred on a SCID or on a normal
background. Bone marrow (BM) from Tgfb1±/± mice produces
Langerhans cells in g-irradiated Tgfb1+/+ recipients, suggesting that
a paracrine effect of TGF-b1 is suf®cient for Langerhans cell
formation (Borkowski et al, 1997b). Furthermore, the skin from
Tgfb1±/± mice does not contain an excess of cytokines, such as
interleukin-1 and tumor necrosis factor-a, which are known to
promote migration of Langerhans cells from the epidermis
(Borkowski et al, 1997a). Thus, the evidence suggests that
precursors of Langerhans cells are normally present in Tgfb1±/±
mice, but that in the absence of TGF-b1 these precursors cannot
enter the epidermis and/or differentiate into Langerhans cells.
A confounding factor in the interpretation of a paracrine effect of
TGF-b1 on Langerhans cell migration into the epidermis is that
Tgfb1±/± mice would be expected to have normal TGF-b2 and
TGF-b3 levels in their tissues and that, on the whole, these TGF-b
use the same receptors as TGF-b1 to signal to cells (Lawrence,
1996). TGF-b are always synthesized as latent proteins which need
to have the latency associated protein (LAP) removed before they
can interact with their receptor (Munger et al, 1997). Multiple
mechanisms have been described by which TGF-b become
activated (Odekon et al, 1994; Nunes et al, 1995, 1996;
Lawrence, 1996; Crawford et al, 1998). Until now, however, no
distinct activation process for TGF-b1, which differs from that for
both of the other TGF-b, has been described. For TGF-b to have a
paracrine effect on Langerhans cell migration into the epidermis, it
would thus have to be activated locally in or near the epidermis. It
is not clear why TGF-b2 and -b3 cannot take the place of TGF-b1
in this respect, although it has been shown that the three TGF-b
knockout mice have distinct phenotypes (Sanford et al, 1997),
suggesting a high degree of functional speci®city. Consequently,
the TGF-b that governs Langerhans cell migration may be
normally brought to the skin by cells that produce/contain TGF-
b1 only. Such cells could include lymphocytes and thrombocytes.
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The presence of life-threatening lymphocytic in®ltrates in the
organs of Tgfb1±/± mice suggests that lymphocytes normally
produce primarily TGF-b1.
In this study, we demonstrate that transfer of Tgfb1+/± SCID BM
can cause the appearance of Langerhans cells in the epidermis of g-
irradiated and unirradiated Tgfb1±/± SCID mice within a few
weeks. Next, we determined that the presence of T lymphocytes
engineered to produce latent TGF-b1 in the skin is suf®cient to
cause the local appearance of Langerhans cells in the epidermis of
Tgfb1±/± SCID mice. Finally, we show that local injections of active
TGF-b2 cause the migration of Langerhans cells into the ear
epidermis of Tgfb1±/± SCID mice.
MATERIALS AND METHODS
Materials Biotin-labeled rat monoclonal antibody to murine I-A/I-E
(clone 2G9) was purchased from Pharmingen (San Diego, CA). TGF-b2
was a generous gift from Dr. John McPherson (Genzyme, Framingham,
MA). Antibodies to murine E-cadherin used included: UMT (rabbit
antibody, donated by Dr. B. M. Gumbiner, Memorial Sloan±Kettering
Cancer Center, New York), DECMA-1 (rat monoclonal antibody,
donated by Dr. R. Kemler from the Max Planck Institute for Immune
Biology, Freiburg, Germany), and ECCD-1 (rat monoclonal antibody,
Zymed Laboratories, South San Francisco, CA).
Mice All animal experiments were performed in accordance with
institutional guidelines and with approval from the Institutional Animal
Care and Use Committee (IACUC). SCID mice heterozygous for the
Tgfb1 null allele were bred in a speci®c pathogen-free room in the
Division of Laboratory Animal Resources (New York University School
of Medicine). Tgfb1±/± SCID mice were smaller in size than their
heterozygous littermates; however, because of their SCID background,
the wasting syndrome was less severe and they lived longer than Tgfb1±/±
mice on a non-SCID background. Litters were genotyped by polymerase
chain reaction analysis as null, heterozygous, or wild type for TGF-b1
(Diebold et al, 1995). Genotyping was carried out on DNA extracted
from the tail tip (0.5 cm). Polymerase chain reaction was performed on
genomic DNA using a combination of three primers: (TGF620) 5¢-
GAGAAGAACTGCTGTGTGCG-3; (TGF622) 5¢-GTGTCCAGGC-
TCCAAATATAGG-3; and (NEO1) 5¢-GCCGAGAAA-GTATCCAT-
3. Thermal cycling was done for 35 cycles under the following
conditions: denaturation at 95°C for 1.5 min, annealing at 57°C for
0.5 min, extension at 72°C for 1.3 min, and a ®nal extension at 72°C
for 5 min
BM transfer from heterozygous littermates to Tgfb1±/± SCID
mice Femurs were taken from two to three heterozygous donors and
the muscles and ligaments were removed. The bones were washed in
Dulbecco's buffered saline (DPBS), cut on both ends, and the BM cells
were ¯ushed out using a 1 ml syringe inserted into the femur. The cells
were resuspended in DPBS, ®ltered through a 70 mm nylon cell strainer,
washed 2 3 with DPBS, counted and resuspended in 200 ml saline for
transfer into littermate Tgfb1±/± recipients. Most of the recipients were
exposed to 300±550 rad g-irradiation (Gammator M, Nordion Intl,
Ontario, Canada) 1 h before cell transfer. The mice received a single
caudal i.v. injection of (50±100) 3 106 BM cells. The BM recipients
were killed 4±42 d after cell transfer for enumeration of epidermal
Langerhans cells.
Subepidermal transfer of myelin basic protein (MBP) speci®c T
cells transduced with TGF-b1 to Tgfb1±/± SCID mice The cloned T
cells used (8±4.G6) were derived from BALB/C mice immunized with
MBP in complete Freud's adjuvant (CFA) (Abromson-Leeman et al,
1995) and were provided by Dr. M. Dorf (Harvard University Medical
School). Cells were reactive to MBP peptide 59±76 (Keck
Biotechnology Resource Center, New Haven, CT). The cells were
transduced with the cDNA (base pairs 352±1550) encoding murine
TGF-b1 as previously described (Chen et al, 1998). These T cells were
stimulated every 2±3 wk by exposure to MBP (10 mg per 106 cells) on
5 3 105 g-irradiated BALB/C spleen cells. The secretion of TGF-b1
was determined by enzyme-linked immunosorbent assay and found to be
independent of exposure to antigen (» 3 ng per 106 cells in 48 h), as
described previously (Chen et al, 1998). Tgfb1±/± mice received a single
injection of 50 ml containing 2 3 105 cloned transduced or control T
cells with and without MBP (50 mg per ml) subepidermally in the ear
skin and subcutaneously at a shaven site on the trunk. The mice were
killed 4±12 d after T cell injection. Some control Tgfb1±/± mice received
50 ml of 50 mg per ml MBP alone, injected into the ear.
TGF-b2 injections into Tgfb1±/± SCID mice One group of mice
received i.p. injections of 200 ng TGF-b2 daily, ®ve injections per
week. The same mice also received local injections of 20 ng TGF-b2 in
the right ear skin, whereas saline was injected in the left ear skin. The
mice were killed 7±21 d later. Another group of mice was similarly
injected, 5 3 per wk, subepidermally with 50 ng of TGF-b2 mixed
with 5% carboxy methyl cellulose (CMC) gel, again into the right ear
skin and at a shaven site on the right side of the trunk. Skin sites on the
left side of the mice were injected with CMC gel alone as controls.
Immunohistochemical localization of Langerhans cells in the
epidermis The dorsal side of the trunk skin of the mice was shaven
and a hair remover (Neet Premier Consumer Products, Inc., Eaglewood,
NJ) was applied to the shaven area. The skin was excised from the
control and treated mice. The subcutaneous fat was scraped off and skin
was washed in DPBS. The pieces of skin were incubated in 2 M NaBr
for 45 min at 37°C, washed in DPBS, and punch biopsies (3 mm) of the
epidermis were taken. The epidermal sheets were ®xed in 95% ethanol
at 4°C for 20 min, washed in DPBS, and incubated with biotin-labeled
anti-I-A/I-E at room temperature for 90 min. The sheets were then
washed in phosphate-buffered saline (3 3 5 min) and incubated with
horseradish peroxidase avidin for 90 min. After washing, the staining was
developed in diaminobenzidine and hydrogen peroxide (5 min) and
enhanced in copper sulfate (2 min). The washed epidermal sheets were
then air dried on a clean glass slide and mounted with permount.
Enumeration of Ia+ Langerhans cells The individual responsible for
counting the Langerhans cells in the epidermal preparations was unaware
of the treatment the mice had received. The Langerhans cell density was
determined using a light microscope with a calibrated eyepiece. The
number of cells per mm2 of epidermis in one central and four peripheral
areas of each epidermal sheet was determined and the value is expressed
as the mean of 5±10 counts 6 SEM per mm2 of epidermis for individual
mice.
RESULTS
BM transfer BM cells taken from littermate Tgfb1+/± SCID mice
were intravenously transferred to Tgfb1±/± mice, in order to
determine the ability of Tgfb1+/± precursor cells to translocate into
Figure 1. Langerhans cells (cells per mm2) in the epidermis of
Tgfb1±/± SCID mice after BM transfer from Tgfb1+/± SCID
donors. Recipients were either unirradiated or exposed to g-irradiation
at 300±550 rad 1 h before cell transfer. The mice received a single
caudal i.v. injection of (50±100) 3 106 femur BM cells. The BM
recipients and control mice were killed 4±42 d after cell transfer for
enumeration of Langerhans cells in epidermal sheets taken from the body
¯anks. Langerhans cell numbers per mm2 are represented as mean counts
from ®ve to 10 different epidermal areas 6 SEM for individual mice. As
epidermal Langerhans cells are totally absent in the epidermis of
untreated or 300 rad g-irradiated Tgfb±/± mice, the appearance of any
number of Ia+ dendritic cells after BM transfer is signi®cant. Other
mononuclear or lymphocytic cells were not observed in the epidermis of
these mice (note that both donor and recipient mice were SCID in these
experiments). Het Contr = mean 6 SEM for 14 heterozygous (Tgfb1+/±)
SCID control mice.
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the epidermis and acquire Langerhans cell morphology in a
Tgfb1±/± environment. Immunohistochemical staining of epidermal
sheets prepared from control Tgfb1±/± mice did not show the
presence of any Ia+ Langerhans cells, whereas the epidermis of the
littermate heterozygous Tgfb+/± SCID mice showed large number
of homogeneously distributed Ia+ Langerhans cells. As shown in
Figs 1 and 2, the epidermis of recipients showed the appearance of
Ia+ Langerhans cells as early as 2 wk after BM transfer, when the
recipients had been sublethally g-irradiated prior to transfer. In
unirradiated Tgfb1±/± mice, it took approximately 4 wk after BM
transfer before a signi®cant number of Langerhans cells were seen in
the recipient's epidermis. The new Langerhans cells in the
epidermis of Tgfb1±/± mice were found to be randomly
distributed and usually appeared as patches of few to several cells
at focal sites. g-irradiated recipients acquired a higher density of
Langerhans cells in their epidermis than did unirradiated recipients.
Peak reconstitution of epidermal Langerhans cells appeared to
occur at about 4 wk after BM transfer, but the degree of
reconstitution was somewhat variable.
Effect of TGF-b1 on Langerhans cell development We next
examined whether subepidermal transfer of cloned MBP-speci®c T
lymphocytes, engineered to produce (latent) TGF-b1, could
induce the migration of Tgfb1±/± dendritic cells into the
epidermis. Tgfb1±/± mice were subepidermally injected at ear and
trunk skin sites with MBP-speci®c TGF-b1 transduced and
untransduced T cells in the presence and absence of MBP
peptide. The results are shown in Fig 3 and Table I.
Interestingly, the Tgfb1±/± mice that received a local injection of
T cells showed the appearance of Langerhans cells in the epidermis
of the ear skin. The local effect of latent TGF-b1 secreting T cells
to induce the appearance of Langerhans cells in the ear epidermis
was more evident in the case of transduced T cells stimulated with
MBP rather than in the absence of this peptide. In an occasional
Tgfb1±/± mouse even untransduced T cells, after stimulation with
MBP peptide, were capable of inducing the appearance of
Langerhans cells in the epidermis of Tgfb1±/± mice. The
Langerhans cell density, however, was much lower in the mice
injected with control T cells than in mice receiving TGF-b1-
transduced T cells. Langerhans cells in the ear epidermis was
observed as early as 4 d after subepidermal transfer of T cells. Peak
numbers of Langerhans cells were seen after 7 d. The newly
detected Langerhans cells in the ear epidermis were larger and had
longer dendritic processes than most of the Langerhans cells in the
ear epidermis of Tgfb1+/±mice. These cells were detected in
patches, mainly at the injection sites. Langerhans cells were
detected only at a few locations and most of the epidermal sheets
were devoid of Ia+ cells. In contrast to the ear epidermis,
Langerhans cells could not be detected in the trunk skin injection
Figure 2. Ia staining of Langerhans cells in epidermal sheets from BM recipients. (A) Tgfb1+/± SCID mouse (body ¯ank skin); (B) unirradiated
Tgfb1±/± SCID mouse, 4 wk after receiving BM; (C) 550 rad irradiated Tgfb1±/± SCID mouse 2 wk after receiving BM, note the increased size in the
Langerhans cells appearing this early after the transfer; (D) 550 rad irradiated Tgfb1±/± SCID mouse 4 wk after receiving BM. Please note that newly
appearing Langerhans cells were often detected in randomly distributed patches of cells. It is therefore impossible to re¯ect the exact density of Ia+
dendritic cells in these photographs. Sheets were stained with biotin-labeled antibody to I-A/IE. Scale bar: = 100 mm.
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Figure 3. Ia staining of Langerhans cells in epidermal sheets from the ears of Tgfb1±/± SCID recipients of local treatment with TGF-b2
or TGF-b1 producing T cells. (A) Tgfb1+/± SCID mouse. Note the normal distribution of a few large and many small Langerhans cells; (B) Tgfb1±/±
SCID mouse after receiving ®ve subepidermal injections of 50 ng TGF-b2 in 5% CMC gel equally spaced over a period of 14 d; (C) Tgfb1±/± SCID
mouse, 12 d after receiving 2 3 105 cloned MBP-speci®c T cells + MBP. Most of the epidermal areas were devoid of Langerhans cells, as they were
only present at the injection site; (D) Tgfb1±/± SCID mouse, 7 d after receiving 2 3 105 cloned TGF-b1 transduced MBP-speci®c T cells + MBP.
Many areas containing Langerhans cells were observed in these recipients. Sheets were stained with biotin-labeled antibody to I-A/IE. Scale bar:
= 100 mm.
Table I. Appearance of Langerhans cells in the epidermis of Tgfb1±/± mice after local injection of 2 3 105 Tgfb+/+ cloned T
cells
Tgfb1±/± mouse/
injected with
Days after
injection
Skin site
studied
No. of Langerhans cells per mm2 6 SEMa
+MBP site ±MBP site pb
TGF-b1 transduced T cells 4 Body
Ear
33 6 19
157 6 73
52 6 32
43 6 29
NS
NS
TGF-b1 transduced T cells 7 Body
Ear
0
176 6 68
0
0 < 0.05
TGF-b1 transduced T cells 7 Body
Ear
0
462 6 53
0
0
< 0.0001
TGF-b1 transduced T cells 11 Body
Ear
0
24 6 32
0
91 6 42 NS
TGF-b1 transduced T cells 12 Body
Ear
0
86 6 34
0
0 NS
Control cloned T cells 7 Body
Ear
0
47.6 6 47.9
0
0
Control cloned T cells 12 Body
Ear
0
61.9 6 61.8
0
0
MBP alone or saline alone 7 Ear 0 0c
aMean 6 SEM of ®ve individual areas of epidermis counted per site. Data are given for individual mice.
bStudent's t-test used to calculate signi®cance of difference between sites of individual mice injected with T cells + MBP vs T cells ± MBP.
cTwo mice with similar results taken together.
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sites. This may be due to the poor local retention of the cells. In the
ear skin, the underlying cartilage might have helped the injected T
cells to remain concentrated at one site for a prolonged period of
time.
Effect of TGF-b2 injections We also examined whether the
local injection of TGF-b2 can induce the appearance of Langerhans
cells in the epidermis of Tgfb1±/± mice. Surprisingly, we detected
Ia+ Langerhans cells in the ear epidermis of the Tgfb1±/± mice that
received repeated subepidermal injections of TGF-b2 (Table II).
The epidermal sheets prepared from solvent-injected control sites
did not show any Ia+ Langerhans cells. Newly appearing
Langerhans cells were again detected only in a few areas at the
injected sites, whereas most of the epidermis lacked Langerhans
cells. These Langerhans cells again had rather large cell bodies and
long dendrites. The trunk skin sites injected with TGF-b2, whether
in saline or in CMC gel, did not show the appearance of any
Langerhans cells.
Dendritic cells in organs other than skin Frozen sections
from lymph nodes, spleen, and tongue from Tgfb1±/± and littermate
Tgfb1+/± SCID mice were stained with anti-Ia and examined for
the presence of Ia+ dendritic cells. The overall density of Ia+
dendritic cells in the lymphoid tissues did not differ between the
Tgfb1±/± and Tgfb1+/± mice; in particular, the periarteriolar areas in
the spleens showed comparable numbers of interdigitating
reticulum cells. In contrast, the subepidermal regions of the
tongue showed only rare dendritic cells in the Tgfb1±/±, whereas
these cells were quite numerous in these regions in the Tgfb1+/±
mice (not shown).
Staining of tongue sections with antibodies to murine E-
cadherin failed to reveal any detectable differences between Tgfb±/±
and Tgfb+/± mice.
DISCUSSION
The literature on the effects of cytokines on Langerhans cell
differentiation in vitro indicates that TGF-b markedly affects
dendritic cells. It is essential for the differentiation of dendritic
cells and/or monocytes into cells that exhibit characteristic
Langerhans cell properties, such as the presence of Birbeck granules
and expression of Lag, Langerin, and E-cadherin (Strobl et al, 1997,
1998; Geissmann et al, 1998; Valladeau et al, 1999; Zhang et al,
1999; Riedl et al, 2000). The CD34+ precursor cells that are
susceptible to the effects of TGF-b are CD14+CD11b±, as opposed
to the CD14+CD11b+ cells, which do not develop into Langerhans
cells with TGF-b (Jaksits et al, 1999). As evident from the results of
others (Borkowski et al, 1997b) and from the ®ndings presented
here, Langerhans cell precursors are present in the Tgfb1±/± SCID
mice, as are the interdigitating dendritic cells in lymphoid tissues.
Our results suggest that TGF-b can act in a paracrine as well as an
autocrine fashion to induce the differentiation into Langerhans
cells. The observation that within 2 wk after transfer of Tgfb1+/±
BM, Langerhans cells are observed in the whole body epidermis of
Tgfb1±/± recipients indicates that the TGF-b1 produced by
nonlymphoid precursor cells present in SCID BM causes the
differentiation of Langerhans cells and their translocation to the
epidermis. It is also possible that mature TGF-b1 producing
monocytes derived from the donor BM become Langerhans cells.
Further studies are needed to determine this. The most likely
interpretation is that autocrine production of TGF-b1 by
Langerhans cell precursors is involved here. This is also in
agreement with the observation that epidermal Langerhans cells
contain TGF-b (Gruschwitz and Hornstein, 1992); however, a
systemic paracrine contribution of TGF-b1 from platelets and/or
neutrophils produced by the SCID donor BM cannot be excluded.
The delay in Langerhans cell appearance after BM transfer and the
facilitating effect from whole body g-irradiation is most likely due
to the need for an expansion of donor cells, which is greater in the
irradiated than in unirradiated recipients. Control mice receiving
irradiation without Tgfb1+/± BM cells failed to show any
Langerhans cell development. On the other hand, the observation
that cloned Th1 cells engineered to produce latent TGF-b1 cause
the rapid local appearance of Langerhans cells in the ear epidermis
near their injection site, proves that paracrine production of TGF-
b1 by T cells is suf®cient to cause Langerhans cell differentiation in
the Tgfb1±/± recipients, most likely from locally present Tgfb1±/±
dermal dendritic cells and/or monocytes. The greater effectiveness
of antigen-activated as opposed to nonstimulated T cells suggests
that the latent TGF-b1 produced by these T cells (which is
unaltered by their stimulation by antigen; Chen et al, 1998) is
activated through the antigen-induced in¯ammation, which attracts
macrophages known to be capable of activating latent TGF-b
(Nunes et al, 1995). In previous studies with MBP-speci®c TGF-b1
transduced T cells, we have shown that these cells protected against
the induction of experimental allergic encephalomyelitis when
injected into mice at the beginning of development of the disease
within 3 d after their activation by MBP in vitro and that this effect
could be prevented by neutralizing anti-TGF-b (Chen et al, 1998).
Table II. Appearance of Langerhans cells in the epidermis of Tgfb1±/± mice after injection of TGF-b2
Mice and
treatmenta
Duration of
treatment
Skin site
studied
No. of Langerhans cells per mm2 6 SEM
TGF-b2 site Control site
Tgfb1±/±, TGF-b2 in saline 1 wk Body
Ear 176 6 109 (5)
0b
0
Tgfb1±/±, TGF-b2 in saline 2 wk Body
Ear 71 6 71 (5)
0b
0
Tgfb1±/±, TGF-b2 in saline 3 wk Body
Ear 124 6 65 (10)
0b
ND
Tgfb1±/±, TGF-b2 in gel 2 wk Body
Ear
0
100 6 79 (5)
0
0
Tgfb1±/±, TGF-b2 in gel 2 wk Body
Ear
0
86 6 41 (5)
0
0
cTgfb1+/± Body
Ear
N/A
N/A
895 6 54 (14)
1298 6 79 (7)
aTgfb1±/± SCID mice treated with TGF-b2 in saline received 200 ng per injection, 5 3per week i.p, and 20 ng per injection, 5 3per week subepidermal in one ear;
control ear sites received saline injections and never showed any Ia+ dendritic cells. Mice treated with TGF-b2 in CMC gel received subepidermal injections at a marked
site on the ¯ank and in one ear: 50 ng per injection, 5 3in 2 wk; control sites received CMC vehicle only and never showed any Ia+ dendritic cells. Langerhans cell num-
bers per mm2 for individual mice are represented as mean counts of Ia+ dendritic cells from 5 to 10 different epidermal areas 6 SEM.
bThese mice were injected i.p. and locally in the ear. The uninjected ¯ank body skin was examined for Langerhans cells.
cEpidermal sheets from these control mice were prepared simultaneously with those from experimental mice.
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Similarly, ovalbumin speci®c cloned T cells transduced with TGF-
b1 were found to protect against ovalbumin-induced lung hyper-
reactivity in vivo and this effect was also prevented by neutralizing
anti-TGF-b (Hansen et al, 2000). Thus, although the T cells were
transduced with the gene for latent TGF-b1, active TGF-b1 was
produced under in¯ammatory conditions in vivo.
This study results indicate that TGF-b2 has an in vivo differen-
tiating effect on Langerhans cells similar to that of TGF-b1 and can
replace TGF-b1 as long as it is injected locally in active form. It is
possible that this effect of TGF-b2 is indirect, but it is clearly not
mediated by induction of TGF-b1 in these mice. It is not known
how the TGF-b isotype-speci®c effects are controlled: (i) by their
speci®c localization in vivo; (ii) by their respective mechanisms of
activation; or (iii) by their relative ability to interact with different
TGF-b receptors. In vitro, the TGF-b appear to act similarly on
most target cells. Moreover, upon injection in active form, many
effects of different TGF-b isotypes in vivo are also indistinguishable,
including their protective effect against autoimmune disease
(Santambrogio et al, 1993) where appropriately timed daily i.p.
injections of 0.1±1.0 mg TGF-b1 or TGF-b2 provided a signi®cant
protective effect. The Tgfb2 and Tgfb3 genes are normally
functional in Tgfb1±/± mice, and whereas the skin content of
TGF-b2 and TGF-b3 is somewhat low in Tgfb1±/± SCID, it is
normal in Tgfb1±/± non-SCID mice (Crowe et al, 2000). Moreover,
observations by others (Borkowski et al, 1997a,b) show that
Langerhans cells are absent from the epidermis also in Tgfb1±/± mice
that have normal TGF-b2 and TGF-b3 mRNA levels in their skin.
It is thus likely that the absence of Langerhans cells in the Tgfb1±/±
epidermis, and the reconstituting effect of locally injected active
TGF-b2 on Langerhans cell development in the ear epidermis
observed in our study, are related to differences in the local
activation mechanism for TGF-b isotypes in the skin such that
active TGF-b2 can promote Langerhans cell differentiation, but is
normally not available in the skin. Thus, our results suggest that,
under normal in vivo conditions, certain isotype-speci®c effects of
TGF-b can be due to differences in the local availability of TGF-b
isotypes in active form rather than to their differences in ability to
interact with particular target cells.
One mechanism by which TGF-b may facilitate the develop-
ment of Langerhans cells from precursors is by upregulating E-
cadherin (Caux et al, 1999; Ito et al, 1999; Jaksits et al, 1999; Riedl
et al, 2000). In vitro studies indicate that murine Langerhans cells
express this Ca2+-dependent homophilic molecule (Tang et al,
1993; Borkowski et al, 1994; Blauvelt et al, 1995; Geissmann et al,
1997; Jakob et al, 1997) and that it mediates Langerhans cell
adherence to keratinocytes (Udey, 1997), as focal accumulations of
E-cadherin and colocalization of b-catenin can be observed in areas
of contact between keratinocytes and Langerhans cells (Jakob et al,
1999). In fact, the migration of Langerhans cells from the epidermis
to the dermis and draining lymph nodes during contact hypersen-
sitivity reactions, ®rst shown to occur by Silberberg et al (1975;
Silberberg-Sinakin et al, 1976), appears to be accompanied by a
downregulation of E-cadherin expression under the in¯uence of
the contact allergen (Aiba et al, 2000) and/or cytokines, such as
tumor necrosis factor-a and interleukin-1 (Jakob and Udey, 1998),
an effect that is counteracted by TGF-b (Geissmann et al, 1999). In
the present study no obvious differences in E-cadherin staining
between Tgfb+/± and Tgfb±/± mouse tissues were found, but
differences in dendritic cell surface staining might not have been
detectable by this staining. Another effect of TGF-b on dendritic
cell precursors likely to be crucial for Langerhans cell recruitment
into the skin, is its upregulating effect on the expression of CCR6
(Sato et al, 2000), the receptor for the keratinocyte produced
chemokine, MIP-3a (Dieu-Nosjean et al, 2000). In contrast, TGF-
b inhibits the upregulation of the receptor for MIP-3b, CCR7, by
tumor necrosis factor-a (Sato et al, 2000). MIP-3b/SLC is
concentrated in T cell areas of secondary lymphoid tissues and is
thought to attract dendritic cells that have left the skin to these areas
(Dieu-Nosjean et al, 1999; Engeman et al, 2000). Thus, the
frequently antagonistic effects of the anti-in¯ammatory cytokine
group of the TGF-b, and the pro-in¯ammatory cytokines, tumor
necrosis factor-a and interleukin-1, also appear responsible for the
movements of dendritic cells in and out of the epidermis.
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